Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
TH7299
AOB10412
CAS: 1415648-20-2
Chemical Name: (4-(3-(4,6-Diamino-2-oxo-1,2-dihydropyridin-3-yl)ureido)benzoyl)-L-glutamic acid
1000 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $58.65 | Total: $293.25 |
| 1 | 10 | $49.68 | Total: $496.80 |
| 1 | 25 | $42.09 | Total: $1,052.25 |
| 1 | 50 | $35.88 | Total: $1,794.00 |
| 1 | 100 | $31.05 | Total: $3,105.00 |
Overview
First-in-class MTHFD2 inhibitor, impairing cancer progression in vivo, preventing thymidine production leading to misincorporation of uracil into DNA and replication stress
Mechanism & Target Enzymes
TH7299 inhibits MTHFD2 (mitochondrial methylenetetrahydrofolate dehydrogenase 2), but it is not very selective: it also inhibits MTHFD2L (an isoform) and MTHFD1.
Some reported potencies:
Enzyme IC₅₀ for TH7299 MTHFD2 ~ 254 nM PMC+2probechem.com+2 MTHFD1 ~ 89 nM PMC+2probechem.com+2 MTHFD2L ~ 126 nM PMC+2probechem.com+2 Binding mode: TH7299 binds in the folate binding site of MTHFD2 / MTHFD2L. The structure of human MTHFD2L in complex with TH7299 has been solved (PDB 7QEI). Chemistry Europe+2RCSB PDB+2
Key interactions include hydrogen bonds between the diaminopyrimidine head group and residues like Asp169, Val145 / Leu147; interactions via the urea linker with Asn101, Lys102, Gln146; pi-stacking with Tyr98; the glutamate tail interacting with Gly324 and Tyr292; plus hydrophobic contacts. Chemistry Europe
Biological Effects & Potential Uses
In cellular assays (acute myeloid leukemia cells in vitro & in vivo), TH7299 (along with related inhibitors) causes:
Reduced replication fork speed
Replication stress
S-phase cell cycle arrest
Apoptosis (cell death) in some settings. PMC
It also leads to disruption of thymidine production, causing uracil misincorporation into DNA. These are hallmarks of perturbing folate-1C metabolism. PMC+1
As of now, TH7299 is for research use only; it is preclinical (not approved for human or veterinary use).
Strengths & Limitations
Strengths:
Nanomolar potency against multiple folate pathway enzymes → can be useful as a tool compound for studying those pathways. PMC
Crystallographic data available → structure-guided drug design possible. RCSB PDB+1
Limitations:
Lack of high isoform selectivity: TH7299 also inhibits MTHFD1 and MTHFD2L, which may lead to off-target effects or toxicity in settings where those isoforms are essential. PMC+1
Lead times / supply may be long for some vendors; stock is sometimes unavailable.
Chemical Properties
| Molecular Formula | C18H20N6O7 |
| Molecular Weight | 432.39 |
| CAS Numbers | 1415648-20-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | (4-(3-(4,6-Diamino-2-oxo-1,2-dihydropyridin-3-yl)ureido)benzoyl)-L-glutamic acid |
| InChl Key | XYBHHWPTCKDMPA-NSHDSACASA-N |
| InChl Code | InChI=1S/C18H20N6O7/c19-10-7-12(20)23-16(28)14(10)24-18(31)21-9-3-1-8(2-4-9)15(27)22-11(17(29)30)5-6-13(25)26/h1-4,7,11H,5-6H2,(H,22,27)(H,25,26)(H,29,30)(H2,21,24,31)(H5,19,20,23,28)/t11-/m0/s1 |
| SMILES Code | O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(NC(NC2=C(N)C=C(N)NC2=O)=O)C=C1)=O |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
TH 7299, TH-7299
References
1) Green AC, et al. Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells. Nat Metab. 2023 Apr;5(4):642-659. doi: 10.1038/s42255-023-00771-5. Epub 2023 Apr 3. PMID: 37012496; PMCID: PMC10132981.2) Bonagas, N., et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat Cancer 3, 156–172 (2022). https://doi.org/10.1038/s43018-022-00331-y